Researchers have found pregabalin highly effective in reducing neuropathic pain and itch in recessive dystrophic epidermolysis bullosa (RDEB), the most prevalent and debilitating form ...

The National Comprehensive Cancer Network (NCCN)-;an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care-;announces the publication of ...

ITDD helps effectively manage chronic pain and spasticity in some patients but requires adherence to best practices and a ...

On shorter reports–under five pages–the Table of Content, List of Illustrations, and Executive Summary parts might not be required. Most common is one-inch margins all around. Use your word-processing ...

Boston biotech Ax­o­nis Ther­a­peu­tics has raised a $115 mil­lion Se­ries A to test whether its oral drug AXN-027 can help pa­tients with fo­cal epilep­sy and … ...

More information: Mikael Åkerlund et al, Genetic associations of neuropathic pain and sensory profile in a deeply phenotyped neuropathy cohort, Pain (2024). DOI: 10.1097/j.pain.0000000000003463 ...

Many clients that I see suffer from chronic pain or chronic medical conditions, often in addition to other disorders like depression, anxiety, PTSD, ADHD, and so forth. Also, I have experienced ...

More information: Carlos Raul Ramirez Medina et al, Clinical indications associated with new opioid use for pain management in the United Kingdom: using national primary care data, Pain (2024).

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo-controlled, ...

The clinical spectrum of CASPR2 antibodies is broad. The complexity and variability in the symptoms caused by CASPR2 antibodies often lead to diagnostic challenges, as evidenced in this case where ...

Objective: To assess the efficacy, safety and impact on quality of life of tramadol in the treatment of neuropathic pain in patients with cancer. Methods: Patients with similar characteristics ...

OK-101 is the first drug candidate to enroll patients specifically diagnosed with Neuropathic Corneal Pain (NCP) in a clinical trial The Phase 2 trial is designed as a randomized, placebo-controlled, ...